The DOI matches its Crossref record; 70 of the 70 references it cites were found in a registry or an index.
CYP2D6 and tamoxifen: DNA matters in breast cancer
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global Cancer Statistics, 2002
Parkin, D. M., Bray, F., Ferlay, J., & Pisani, P. (2005) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.55.2.74 · Cited by 18,196
International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels
Catterall, W. A., Chandy, K. G., Clapham, D. E., Gutman, G. A., Hofmann, F., Harmar, A. J., Abernethy, D. R., & Spedding, M. (2003) · Pharmacological Reviews · doi:10.1124/pr.55.4.5 · Cited by 7,126
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Pharmacogenomics — Drug Disposition, Drug Targets, and Side Effects
Evans, W. E., & McLeod, H. L. (2003) · New England Journal of Medicine · doi:10.1056/nejmra020526 · Cited by 1,769
Self-citationCoombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052258 · Cited by 1,577
Tamoxifen in the Treatment of Breast Cancer
Osborne, C. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811263392207 · Cited by 1,320
Ingelman-Sundberg, M., Sim, S. C., Gomez, A., & Rodriguez-Antona, C. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2007.09.004 · Cited by 1,166
Ingelman-Sundberg, M. (2005) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500285 · Cited by 1,108
Nelson, D. R., Zeldin, D. C., Hoffman, S. M., Maltais, L. J., Wain, H. M., & Nebert, D. W. (2004) · Pharmacogenetics · doi:10.1097/00008571-200401000-00001 · Cited by 1,027
Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer
Gnant, M., Mlineritsch, B., Schippinger, W., Luschin-Ebengreuth, G., Pöstlberger, S., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Bjelic-Radisic, V., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0806285 · Cited by 1,025
Sachse, C., Brockmöller, J., Bauer, S., & Roots, I. (1997) · Europe PMC (PubMed Central) · Cited by 973
Jin, Y., Desta, Z., Stearns, V., Ward, B., Ho, H., Lee, K.-H., Skaar, T., Storniolo, A. M., Li, L., Araba, A., et al. (2005) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dji005 · Cited by 951
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
Desta, Z., Zhao, X., Shin, J.-G., & Flockhart, D. A. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241120-00002 · Cited by 942
Howell, A. (1998) · PubMed · Cited by 901
Stearns, V. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg108 · Cited by 850
Goetz, M. P., Rae, J. M., Suman, V. J., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., Flockhart, D. A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.3266 · Cited by 791
The CYP2D6 Activity Score: Translating Genotype Information into a Qualitative Measure of Phenotype
Gaedigk, A., Simon, S., Pearce, R., Bradford, L., Kennedy, M., & Leeder, J. (2008) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100406 · Cited by 779
CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants
Bradford, L. D. (2002) · Pharmacogenomics · doi:10.1517/14622416.3.2.229 · Cited by 773
Moving towards individualized medicine with pharmacogenomics
Evans, W. E., & Relling, M. V. (2004) · Nature · doi:10.1038/nature02626 · Cited by 768
Loprinzi, C. L., Kugler, J. W., Sloan, J. A., Mailliard, J. A., LaVasseur, B. I., Barton, D. L., Novotny, P. J., Dakhil, S. R., Rodger, K., Rummans, T. A., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03403-6 · Cited by 737
SIM, S., RISINGER, C., DAHL, M., AKLILLU, E., CHRISTENSEN, M., BERTILSSON, L., & INGELMANSUNDBERG, M. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.10.002 · Cited by 732
Desta, Z., Ward, B. A., Soukhova, N. V., & Flockhart, D. A. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.065607 · Cited by 645
Newton, D. J., Wang, R. W., & Lu, A. Y. (1995) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)06500-6 · Cited by 605
International Union of Pharmacology. LXIV. Estrogen Receptors
Dahlman-Wright, K., Cavailles, V., Fuqua, S. A., Jordan, V. C., Katzenellenbogen, J. A., Korach, K. S., Maggi, A., Muramatsu, M., Parker, M. G., & Gustafsson, J.-Å. (2006) · Pharmacological Reviews · doi:10.1124/pr.58.4.8 · Cited by 583
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen
Goetz, M. P., Knox, S. K., Suman, V. J., Rae, J. M., Safgren, S. L., Ames, M. M., Visscher, D. W., Reynolds, C., Couch, F. J., Lingle, W. L., et al. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-006-9428-0 · Cited by 552
BORGES, S., DESTA, Z., LI, L., SKAAR, T., WARD, B., NGUYEN, A., JIN, Y., STORNIOLO, A., NIKOLOFF, D., & WU, L. (2006) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2006.03.013 · Cited by 487
Schroth, W., Antoniadou, L., Fritz, P., Schwab, M., Muerdter, T., Zanger, U. M., Simon, W., Eichelbaum, M., & Brauch, H. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.2705 · Cited by 467
Osborne, C. K., Shou, J., Massarweh, S., & Schiff, R. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.865s.11.2 · Cited by 462
Johnson, M. D., Zuo, H., Lee, K.-H., Trebley, J. P., Rae, J. M., Weatherman, R. V., Desta, Z., Flockhart, D. A., & Skaar, T. C. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000025406.31193.e8 · Cited by 456
Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity.
Xu, Y., & Villalona-Calero, M. A. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf337 · Cited by 413
Howell, A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)74803-0 · Cited by 398
Cellular and Molecular Pharmacology of Antiestrogen Action and Resistance
Clarke, R., Leonessa, F., Welch, J. N., & Skaar, T. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01479-0 · Cited by 397
Estrogen receptor β: Potential functional significance of a variety of mRNA isoforms
Lewandowski, S., Kalita, K., & Kaczmarek, L. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03015-6 · Cited by 374
Hemeryck, A., & Belpaire, F. (2002) · Current Drug Metabolism · doi:10.2174/1389200023338017 · Cited by 368
Spina, E., Santoro, V., & D'Arrigo, C. (2008) · Clinical Therapeutics · doi:10.1016/s0149-2918(08)80047-1 · Cited by 361
Lim, Y. C., Desta, Z., Flockhart, D. A., & Skaar, T. C. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0926-7 · Cited by 309
Nowell, S. A., Ahn, J., Rae, J. M., Scheys, J. O., Trovato, A., Sweeney, C., MacLeod, S. L., Kadlubar, F. F., & Ambrosone, C. B. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-7751-x · Cited by 306
Identification of the primary gene defect at the cytochrome P450 CYP2D locus
Gough, A. C., Miles, J. S., Spurr, N. K., Moss, J. E., Gaedigk, A., Eichelbaum, M., & Wolf, C. R. (1990) · Nature · doi:10.1038/347773a0 · Cited by 302
Wegman, P., Elingarami, S., Carstensen, J., Stål, O., Nordenskjöld, B., & Wingren, S. (2007) · Breast Cancer Research · doi:10.1186/bcr1640 · Cited by 288
Lim, H.-S., Ju Lee, H., Seok Lee, K., Sook Lee, E., Jang, I.-J., & Ro, J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.4850 · Cited by 268
Kaufmann, M., Jonat, W., Hilfrich, J., Eidtmann, H., Gademann, G., Zuna, I., & von Minckwitz, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8054 · Cited by 267
Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients
Wegman, P., Vainikka, L., Stål, O., Nordenskjöld, B., Skoog, L., Rutqvist, L.-E., & Wingren, S. (2005) · Breast Cancer Research · doi:10.1186/bcr993 · Cited by 243
Wu, X., Hawse, J. R., Subramaniam, M., Goetz, M. P., Ingle, J. N., & Spelsberg, T. C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3933 · Cited by 225
2002 Annual Report of the Korea Central Cancer Registry: Based on Registered Data from 139 Hospitals
Shin, H., Jung, K., Won, Y., et al. (2004) · Cancer Research and Treatment · doi:10.4143/crt.2004.36.2.103 · Cited by 216
CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver.
Dehal, S. S., & Kupfer, D. (1997) · PubMed · Cited by 187
Pharmacokinetics of Selective Estrogen Receptor Modulators
Morello, K. C., Wurz, G. T., & DeGregorio, M. W. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342040-00004 · Cited by 174
Kimmick, G. G., Lovato, J., McQuellon, R., Robinson, E., & Muss, H. B. (2006) · The Breast Journal · doi:10.1111/j.1075-122x.2006.00218.x · Cited by 160
Comparative Metabolic Capabilities and Inhibitory Profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17
Shen, H., He, M. M., Liu, H., Wrighton, S. A., Wang, L., Guo, B., & Li, C. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015354 · Cited by 160
Perez, E. A. (2007) · Annals of Oncology · doi:10.1093/annonc/mdm263 · Cited by 142
Opportunities and Strategies for Breast Cancer Prevention Through Risk Reduction
Mahoney, M. C., Bevers, T. B., Linos, E., & Willett, W. C. (2008) · CA A Cancer Journal for Clinicians · doi:10.3322/ca.2008.0016 · Cited by 127
The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users
Bijl, M. J., van Schaik, R. H. N., Lammers, L. A., Albert Hofman, D., Vulto, A. G., van Gelder, T., Stricker, B. H. C., & Visser, L. E. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0272-2 · Cited by 126
Unraveling the Mechanisms of Endocrine Resistance in Breast Cancer: New Therapeutic Opportunities
Massarweh, S. A., & Schiff, R. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2540 · Cited by 125
Impaired Tamoxifen Metabolism Reduces Survival in Familial Breast Cancer Patients
Newman, W. G., Hadfield, K. D., Latif, A., Roberts, S. A., Shenton, A., McHague, C., Lalloo, F. I., Howell, S. J., & Evans, D. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5235 · Cited by 116
Nishiyama, T., Ogura, K., Nakano, H., Ohnuma, T., Kaku, T., Hiratsuka, A., Muro, K., & Watabe, T. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00994-2 · Cited by 109
Sequence-based CYP2D6 Genotyping in the Korean Population
Lee, S., Sohn, K.-M., Ryu, J. Y., Yoon, Y. R., Shin, J., & Kim, J.-W. (2006) · Therapeutic Drug Monitoring · doi:10.1097/01.ftd.0000211823.80854.db · Cited by 97
Punglia, R. S., Burstein, H. J., Winer, E. P., & Weeks, J. C. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn100 · Cited by 89
Hayes, D. F., Stearns, V., Rae, J. M., & Flockhart, D. A. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn271 · Cited by 84
Parte, P. P., & Kupfer, D. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.000802 · Cited by 83
Wennerholm, A., Johansson, I., Hidestrand, M., Bertilsson, L., Gustafsson, L. L., & Ingelman‐Sundberg, M. (2001) · Pharmacogenetics · doi:10.1097/00008571-200107000-00005 · Cited by 78
Blevins‐Primeau, A. S., Sun, D., Chen, G., Sharma, A. K., Gallagher, C. J., Amin, S., & Lazarus, P. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3708 · Cited by 75
Development and Trends of Surgical Modalities for Breast Cancer in China: A Review of 16-Year Data
Yu, K., Di, G., Wu, J., Lu, J.-S., Shen, K.-W., Shen, Z., & Shao, Z.-M. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9436-2 · Cited by 70
Lash, T. L., Pedersen, L. H., Cronin-Fenton, D. P., Ahern, T. P., Rosenberg, C. L., Lunetta, K. L., Silliman, R. A., Hamilton-Dutoit, S. J., Garne, J. P., Ewertz, M., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604533 · Cited by 64
Ogura, K., Ishikawa, Y. T., Kaku, T., Nishiyama, T., Ohnuma, T., Muro, K., & Hiratsuka, A. (2006) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.01.004 · Cited by 50
Estrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen
NTUKIDEM, N., Nguyen, A., Stearns, V., Rehman, M., Schott, A. F., Skaar, T. C., Jin, Y., Blanche, P. J., Li, L., Lemler, S. M., et al. (2007) · Clinical Pharmacology & Therapeutics · doi:10.1038/sj.clpt.6100343 · Cited by 43
Parton, M., & Smith, I. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.3016 · Cited by 34
Cited by
Biological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Wnt signaling in breast cancer: biological mechanisms, challenges and opportunities
Xu, X., Zhang, M., Xu, F., & Jiang, S. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01276-5 · Cited by 588
Liang, J., & Shang, Y. (2013) · Annual Review of Physiology · doi:10.1146/annurev-physiol-030212-183708 · Cited by 314
The molecular pathology of cancer
Harris, T. J. R., & McCormick, F. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.41 · Cited by 276
Mürdter, T. E., Schroth, W., Bacchus-Gerybadze, L., Winter, S., Heinkele, G., Simon, W., Fasching, P. A., Fehm, T., Eichelbaum, M., Schwab, M., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.27 · Cited by 270
Metadata
- Authors
- Hoskins, J. M., Carey, L. A., & McLeod, H. L.
- Venue
- Nature Reviews Cancer
- Published
- 2009-08
- Volume
- 9
- Issue
- 8
- Pages
- 576-586
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2013479777
- Cited by
- 322
- References
- 70
- FWCI
- 7.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.